Patents for A61P 35 - Antineoplastic agents (221,099) |
---|
09/24/2014 | EP2780028A1 Use of protein s for treating cancer |
09/24/2014 | EP2780017A1 Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway |
09/24/2014 | EP2780011A1 Combination therapy for ovarian cancer |
09/24/2014 | EP2780010A1 Combination therapy of hsp90 inhibitors with braf inhibitors |
09/23/2014 | US8841433 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences |
09/23/2014 | US8841257 Inhibitors of STAT3 and uses thereof |
09/23/2014 | US8841256 P2X7: inhibition of epithelial cancers and papillomas |
09/23/2014 | US8841254 Method for treatment of anxiety |
09/23/2014 | US8841251 Method for making a homogenous vaccine composition comprising a conjugate of EGF and 64K for the treatment of tumors |
09/23/2014 | US8840934 Uses of ammonium chloride |
09/23/2014 | US8840902 Tumor vaccination involving a humoral immune response against self-proteins |
09/23/2014 | US8840896 Anti-HER2 antibody variants |
09/23/2014 | US8840874 Vascular delivery systems |
09/23/2014 | CA2758019C Imidaz0[1,2-a] pyridine-6-carboxamide derivatives, their use for the treatment of colon cancer and their method of manufacture |
09/23/2014 | CA2752527C Indole/benzimidazole compounds as mtor kinase inhibitors |
09/23/2014 | CA2725390C Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer |
09/23/2014 | CA2696185C Use of taurolidine and derivatives thereof in the treatment of cancer by induction of apoptosis |
09/23/2014 | CA2691357C Antibodies to human programmed death receptor pd-1 |
09/23/2014 | CA2659050C Camptothecin derivatives with antitumor activity |
09/23/2014 | CA2658902C Camptothecin derivatives with antitumor activity |
09/23/2014 | CA2638902C Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies |
09/23/2014 | CA2490758C Dosage form of recombinant humanized monoclonal antibody 2c4 |
09/23/2014 | CA2473039C Novel anti-igf-ir antibodies and uses thereof |
09/23/2014 | CA2378182C Compositions and methods for the treatment of tumors |
09/18/2014 | WO2014146137A1 Immunoassay of s-adenosylmethionine using analogs thereof and personalized therapeutics |
09/18/2014 | WO2014145907A1 Targeting t cells with heterodimeric proteins |
09/18/2014 | WO2014145813A1 Abiraterone acetate formulation |
09/18/2014 | WO2014145715A1 Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
09/18/2014 | WO2014145693A1 Metabolites of n-[3-fluoro-4-({ 6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
09/18/2014 | WO2014145403A1 Substituted indol-5-ol derivatives and their therapeutic applications |
09/18/2014 | WO2014145242A1 Peptide-coated polymer carriers |
09/18/2014 | WO2014145207A1 Substituted gemcitabine bicyclic amide analogs and treatment methods using same |
09/18/2014 | WO2014145118A1 Resorufin derivatives for treatment of oxidative stress disorders |
09/18/2014 | WO2014145090A1 Biologically active molecules, conjugates thereof, and therapeutic uses |
09/18/2014 | WO2014145051A1 Heterocyclic compounds and uses thereof |
09/18/2014 | WO2014144871A1 Cytotoxic and anti-mitotic compounds, and methods of using the same |
09/18/2014 | WO2014144859A1 Treatment method and product for uterine fibroids using purified collagenase |
09/18/2014 | WO2014144804A1 Biomarkers for radiation treatment |
09/18/2014 | WO2014144747A1 Substituted 6,5-fused bicyclic heteroaryl compounds |
09/18/2014 | WO2014144659A1 Pyrazole derivatives as prmt1 inhibitors and uses thereof |
09/18/2014 | WO2014144455A1 1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof |
09/18/2014 | WO2014143960A1 Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl) methanone compounds as cancer cell growth inhibitors |
09/18/2014 | WO2014143835A1 Combination/adjuvant therapy for wt-1-positive disease |
09/18/2014 | WO2014143768A1 Tricyclic heterocycles as bet protein inhibitors |
09/18/2014 | WO2014143765A1 Anti-egfr antibody drug conjugate formulations |
09/18/2014 | WO2014143659A1 Irreversible covalent inhibitors of the gtpase k-ras g12c |
09/18/2014 | WO2014143643A1 Acyclic nucleoside phosphonate diesters |
09/18/2014 | WO2014143612A1 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity |
09/18/2014 | WO2014143242A1 Compounds useful as inhibitors of atr kinase |
09/18/2014 | WO2014143241A1 Compounds useful as inhibitors of atr kinase |
09/18/2014 | WO2014143240A1 Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
09/18/2014 | WO2014143051A1 Fluorinated pyrimidine analogs and methods of use thereof |
09/18/2014 | WO2014142995A1 Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer |
09/18/2014 | WO2014142660A1 Combinations of inhibitors of mek, egfr and erbb2 in the treatment of kras-mutant lung cancer and kras-mutant colon cancer |
09/18/2014 | WO2014142507A1 Composition for preventing or treating colon cancer, containing 3,6-anhydro-l-galactose |
09/18/2014 | WO2014142291A1 Hydrate of fluorine compound, and crystals thereof |
09/18/2014 | WO2014142235A1 Microvesicle, and manufacturing method for same |
09/18/2014 | WO2014142220A1 Anti-tumor agent |
09/18/2014 | WO2014142102A1 Liquid aqueous composition |
09/18/2014 | WO2014142092A1 Novel pi polyamide |
09/18/2014 | WO2014141652A1 Smyd3 peptides and vaccines containing the same |
09/18/2014 | WO2014141288A1 The art, method, manner, process and system of a nano-biomineral for multi-modal contrast imaging and drug delivery |
09/18/2014 | WO2014141287A1 The art, method, manner, process and system of multifunctional nanobiomaterial for molecular imaging and drug- delivery |
09/18/2014 | WO2014141153A1 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
09/18/2014 | WO2014141118A1 Imidazo[4,5-c]quinoline derivatives and uses thereof |
09/18/2014 | WO2014141104A1 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
09/18/2014 | WO2014141094A1 Anticancer conjugate |
09/18/2014 | WO2014141082A1 Agent for the prophylaxis and/or treatment of neoplastic diseases |
09/18/2014 | WO2014141015A1 Pyrazolylbenzo[d]imidazole derivatives |
09/18/2014 | WO2014140929A1 Process for drying bendamustine hydrochloride monohydrate |
09/18/2014 | WO2014140797A1 MicroRNA-BASED APPROACH TO TREATING MALIGNANT PLEURAL MESOTHELIOMA |
09/18/2014 | WO2014140704A1 Indole compounds that activate ampk |
09/18/2014 | WO2014140695A1 Solid oral formulation of a pyrrolidine substituted flavone compound |
09/18/2014 | WO2014140644A1 Chemical entities |
09/18/2014 | WO2014140597A1 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors |
09/18/2014 | WO2014140592A1 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as ssao inhibitors |
09/18/2014 | WO2014140591A1 New compounds |
09/18/2014 | WO2014140543A1 Hypoosmotic solutions for lymph node detection |
09/18/2014 | WO2014140313A1 Macrocyclic salt-inducible kinase inhibitors |
09/18/2014 | WO2014140286A1 Anti-tumoral composition comprising a pi3kbeta inhibitor and a raf inhibitor, to overcome cancer cells resistance |
09/18/2014 | WO2014140203A1 Particles comprising luminescent lanthanide complexes |
09/18/2014 | WO2014140174A1 Pyrrolobenzodiazepines and conjugates thereof |
09/18/2014 | WO2014140159A1 Dosage form comprising crizotinib |
09/18/2014 | WO2014140075A1 Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
09/18/2014 | WO2014139970A1 Processes and intermediates for preparing a medicament |
09/18/2014 | WO2014139882A1 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
09/18/2014 | WO2014139468A1 Fusion protein molecules and method of use |
09/18/2014 | WO2014139465A1 Novel pyrimidine and pyridine compounds and their usage |
09/18/2014 | WO2014139458A1 Fused ring compound containing pyrimidine or pyridine and use thereof as anti-tumour drug |
09/18/2014 | WO2014139456A1 Application of aluminum hydroxide in preparation of medicament for treatment of liver cancer |
09/18/2014 | WO2014139443A1 Low immunogenicity human cell and preparation method therefor |
09/18/2014 | WO2014139425A1 Anti-blys monoclonal antibody and pharmaceutical composition containing antibody |
09/18/2014 | WO2014139391A1 Substituted pyridine compounds as kinases inhibitors |
09/18/2014 | WO2014139328A1 Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
09/18/2014 | WO2014139326A1 Pyrazolo compounds and uses thereof |
09/18/2014 | WO2014139325A1 Therapeutic compounds and compositions |
09/18/2014 | WO2014139324A1 Tetracyclic bromodomain inhibitors |
09/18/2014 | WO2014139282A1 Pharmaceutical compositions for treating cancer of genital system and preparation method therefor |
09/18/2014 | WO2014139227A1 Lump sugar, and production method and application thereof |
09/18/2014 | WO2014139145A1 Novel pyrimidine and pyridine compounds and usage thereof |